Altimmune (ALT) Appoints Richard Eisenstadt as CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Grand Canyon Education places CFO on leave amid stock trade probe
- Funds sell $44bn in semiconductors on AI concerns
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
December 13, 2021 6:00 AM ESTGAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. Mr. Eisenstadt succeeds Will Brown, who is leaving Altimmune to pursue other opportunities.
We are excited to welcome Rich to Altimmune and our executive management team. His extensive experience in financing and managing drug development and commercial operations will help ensure the companys continued success, said Vipin K. Garg Ph.D.,... More
